ストックスクリーナーアプリを入手
1.67
2.34%
-0.04
前日終値:
$1.71
開ける：
$1.73
24時間の取引高:
1.16M
Relative Volume:
1.36
時価総額：
$111.92M
収益：
当期純損益:
$-122.44M
株価収益率:
-0.7409
EPS:
-2.254
ネットキャッシュフロー:
$-103.79M
1週間 パフォーマンス:
-3.47%
1か月 パフォーマンス:
-12.57%
6か月 パフォーマンス:
-79.33%
1年 パフォーマンス:
-81.02%
1日の値動き範囲:
$1.65
$1.7489
1週間の範囲:
$1.56
$1.7489
52週間の値動き範囲:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
名前
Engene Therapeutics Inc
セクター
電話
(514) 332-4888
住所
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.67 | 111.92M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-18 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2026-05-08 | ダウングレード | Citizens | Mkt Outperform → Mkt Perform |
| 2026-05-08 | ダウングレード | Guggenheim | Buy → Neutral |
| 2026-05-08 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-05-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-05-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2026-05-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2026-05-08 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2026-05-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2026-04-13 | 開始されました | WBB Securities | Buy |
| 2026-01-30 | 開始されました | Jefferies | Buy |
| 2025-11-11 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | 開始されました | Piper Sandler | Overweight |
| 2025-02-14 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-27 | 開始されました | Raymond James | Outperform |
| 2024-11-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2024-04-22 | 開始されました | Wells Fargo | Overweight |
| 2024-04-15 | 開始されました | Guggenheim | Buy |
| 2024-03-28 | 開始されました | UBS | Buy |
| 2024-03-08 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Engene Therapeutics Inc (ENGN) 最新ニュース
Form 4 enGene Therapeutics Inc. For: 25 September By Investing.com - Investing.com Canada
Form 4 enGene Therapeutics Inc. For: 25 September - Investing.com India
Form 4 enGene Therapeutics Inc. For: 25 September By Investing.com - Investing.com UK
At $1.97 a share, enGene Therapeutics (ENGN) interim medical chief bought 5,102 shares. - Stock Titan
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market - Seeking Alpha
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
EnGene Therapeutics Posts $32.501M Net Loss and $0.47 EPS for Q3 2026 (NASDAQ: ENGN) - kalkinemedia.com
enGene Therapeutics Inc. reports results for the quarter ended July 31Earnings Summary - TradingView
Engene Holdings stock rating maintained at Market Perform by Citizens - Investing.com Nigeria
Engene Holdings stock rating maintained at Market Perform by Citizens - Investing.com Canada
enGene at Wells Fargo conference: bladder cancer push gains focus By Investing.com - Investing.com Canada
ENGN: Detalimogene voraplasmid nears pivotal data and FDA filing, targeting broad NMIBC adoption - TradingView
enGene at Wells Fargo conference: bladder cancer push gains focus By Investing.com - Investing.com India
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene at Wells Fargo conference: bladder cancer push gains focus By Investing.com - Investing.com UK
enGene advances detalimogene bladder cancer therapy filing - grafa.com
enGene Reports $266.3M Cash, Reaffirms Q4 BLA Submission for detalimogene - Minichart
enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary - TradingView
enGene Reports Q3 2026: $266.3M Cash, $32.5M Net Loss; BLA Filing Planned 4Q26 - TradingView
Gene-therapy firm enGene (ENGN) halves its staff as losses climb - Stock Titan
ENGN 10-Q FilingsenGene Therapeutics Inc SEC 10-Q - Stock Titan
enGene Reports $32.5 Million Third-Quarter Net Loss and $266.3 Million Cash - Quiver Quantitative
A bladder cancer treatment study reported complete responses in 54% of patients - Stock Titan
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update - Business Wire
enGene Therapeutics Inc. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
EnGene to Spotlight Bladder Cancer Gene Therapy at Major Investor Conferences - TipRanks
enGene to Participate in Upcoming Investor Conferences - Yahoo Finance
enGene to Participate in Upcoming Investor Conferences - Business Wire
Deep Track Capital Exits enGene Therapeutics (ENGN) Stake in Sec - GuruFocus
enGene Holdings Warrants (ENGNW) Surge 13.55% to $0.24 as Gene Therapy Speculation Heats UpVolatility Skew - careplusvn.com
enGene Holdings Warrants (ENGNW) Surge 13.55% to $0.24 as Gene Therapy Speculation Heats UpValue Stock Ideas - dars.gov.et
enGene Holdings Warrants (ENGNW) Surge 13.55% to $0.24 as Gene Therapy Speculation Heats UpZigzag Correction - dars.gov.et
enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside - TradingView
enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen - MarketBeat
Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan
enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan
Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership - Stock Titan
Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna - Stock Titan
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - MarketBeat
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - Yahoo Finance
Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene - Stock Titan
enGene Therapeutics Inc. (S0N0.F) analyst ratings, estimates and forecasts - uk.finance.yahoo.com
enGene highlights detalimogene NMIBC KOL insights and outlook - TipRanks
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder CancerSlideshow (NASDAQ:ENGN) 2026-08-11 - Seeking Alpha
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
enGene Therapeutics Inc. (S0N0.F) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Business Wire
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – BOATS:ENGNW - TradingView
Engene Therapeutics Inc (ENGN) 財務データ
収益
当期純利益
現金流量
EPS
4.22%
大文字化:
|
ボリューム (24 時間):